Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmab…
An institutional-grade, numbers-driven thesis on MGX — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Metagenomi, Inc. Common Stock (MGX) 53/100 with a 12-month base-case forecast of $14.50 — +1050.8% versus the current price of $1.26. Metagenomi, Inc. Common Stock trades at $1.26 in the Healthcare sector, with a market capitalisation of $47.4M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for MGX is $14.50, implying +1050.8% versus the current price. The model's 12-month scenario range runs from $0.72 (bear) to $1.01 (bull), with a base case of $0.83.
On the fundamentals, Metagenomi, Inc. Common Stock shows a P/E of -0.5, trailing revenue of $25.2M, revenue growth of -51.8% YoY. This page also tracks MGX's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
MGX currently carries a TradersQuant composite score of 53/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $14.50 implies +1050.8% from $1.26. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for MGX is $14.50, about +1050.8% versus the latest price of $1.26. Consensus is based on 5 analysts.
TradersQuant's 12-month model forecast for MGX is a base case of $0.83, ranging from $0.72 (bear) to $1.01 (bull), an expected return of -33.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for MGX over the next 12 months is $0.83 in the base case (bear $0.72, bull $1.01), versus today's price of $1.26. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for MGX — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates MGX's fair value at $14.50, implying +1050.8% of expected upside versus the current price.
Metagenomi, Inc. Common Stock does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
